Full Breakdown
Progress Toward Marijuana Reclassification Under Trump Administration
3/22/2026, 9:11:27 PM
Current Status of Marijuana Reclassification
The U.S. government is moving closer to reclassifying marijuana from a Schedule 1 drug, which includes substances like heroin, to a Schedule 3 classification, similar to medications like codeine-laced Tylenol. This shift is part of President Donald Trump's executive order issued on December 18, 2025, aimed at easing federal restrictions on cannabis. The reclassification is being spearheaded by U.S. Attorney General Pam Bondi, who is finalizing the necessary rule changes for publication in the Federal Register. However, the timeline for this process remains uncertain, with no set deadline for completion.
Implications for the Cannabis Industry
The reclassification of marijuana is expected to significantly impact the cannabis industry, valued at approximately $70 billion. Currently, many banks, including JPMorgan Chase, Bank of America, and Citigroup, refrain from lending to cannabis businesses due to the federal prohibition. The change to Schedule 3 would allow for more mainstream financing and banking opportunities, potentially unlocking the industry's full growth potential. Despite many states having decriminalized marijuana, the lack of federal approval continues to hinder its expansion.
Investor Sentiment and Industry Optimism
Investors in the cannabis sector are expressing optimism regarding the impending reclassification. Marc Cohodes, a former hedge-fund manager and investor in Glass House Brands, believes that the timing for legalization is imminent, especially with Dr. Mehmet Oz, the administrator of the White House’s Centers for Medicare and Medicaid Services, advocating for a pilot program for medical marijuana. Doug Kass, a hedge-fund investor at Seabreeze Partners, noted that major cannabis companies have recently refinanced their debts, indicating a belief that progress toward legalization is underway.
Criticism and Concerns
Despite the optimism, there are concerns regarding the Trump administration's approach to marijuana. Some critics suggest that the administration's focus on medical marijuana over recreational use reflects a lingering skepticism about cannabis. President Trump, who does not consume alcohol, reportedly aims to keep marijuana away from children, which may influence the administration's cautious stance. Additionally, the lengthy review process by the Department of Justice has left many industry players frustrated and uncertain about the future.
Official Statements & Responses
An anonymous source familiar with the DOJ's handling of the reclassification stated, “This could happen relatively soon. It is a process and it’s still being discussed internally.” Meanwhile, Cohodes emphasized the urgency of the situation, stating, “Dr. Oz made it clear that CBD for Medicare will be available April 15, and we are getting very close to that date.” Kass added, “The major pot companies all were able to refinance their debt in recent weeks meaning there is a belief that things are moving toward legalization.”
What's Next
The Justice Department is expected to publish the new final rule soon, officially reclassifying marijuana from a Schedule 1 to a Schedule 3 drug. This development could pave the way for significant changes in the cannabis industry, allowing it to operate more freely within the financial system and potentially leading to broader acceptance of marijuana use across the United States.
